GLP-1 Beyond Weight Loss: Cardiometabolic and Systemic Benefits The most compelling evidence for GLP-1 extends beyond weight loss
Cell 110 , 673687
Preclinical studies suggest GLP-1 agonists may reduce certain inflammatory markers, but these findings have not been validated in rheumatoid arthritis clinical trials
Drucker has served as an advisor or consultant within the past 12 months to Amylin Pharmaceuticals, Arisaph Pharmaceuticals, Diartis Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Merck Research Laboratories, Novo Nordisk, NPS Pharmaceuticals, Takeda and Transition Pharmaceuticals
The abdomen typically gives the most consistent absorption
( PMID: 30350785 ) Steveling EH, Winzeler B, Bircher AJ (2014) Systemic allergic reaction to the GLP-1 receptor agonist exenatide